comparemela.com
Home
Live Updates
Nuvalent Announces First Patient Dosed in ARROS-1 Phase 1/2 Clinical Trial of NVL-520, its Novel ROS1-selective Inhibitor : comparemela.com
Nuvalent Announces First Patient Dosed in ARROS-1 Phase 1/2 Clinical Trial of NVL-520, its Novel ROS1-selective Inhibitor
/PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a biotechnology company creating precisely targeted therapies for clinically proven kinase targets in cancer,...
Related Keywords
Cambridge
,
Cambridgeshire
,
United Kingdom
,
Christopher Turner
,
James Porter
,
Linkedin
,
Nuvalent Inc
,
Twitter
,
Nasdaq
,
Prnewswire Nuvalent Inc
,
Exchange Commission
,
Company Quarterly Report On Form
,
Product Development Regulatory Affairs For Nuvalent
,
Chief Medical Officer
,
Darlene Noci
,
Senior Vice President
,
Product Development
,
Regulatory Affairs
,
Chief Executive Officer
,
Private Securities Litigation Reform Act
,
Quarterly Report
,
Nuvalent
,
Nc
,
Health Care Amp Hospitals
,
Medical Pharmaceuticals
,
Biotechnology
,
Clinical Trials Amp Medical Discoveries
,
comparemela.com © 2020. All Rights Reserved.